TrialCancer immunology research2019

Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses.

James W Welsh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.